Name: Adial Pharmaceuticals, Inc. (ADIL) Financial Statements
Creator: FinSpry

Adial Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Adial Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.13	0.00	0.00
Cost of Revenue	0.00	0.00	0.55	0.00	0.00
Gross Profit	0.00	0.00	-0.42	0.00	0.00
Operating Expenses
Research & Development	3.23	1.27	1.95	8.40	5.85
Selling, General & Administrative	5.06	5.62	8.91	9.34	5.07
Operating Expenses	8.28	6.89	10.86	17.74	10.93
Operating Income	-8.28	-6.89	-10.86	-17.74	-10.93
Other Income/Expense
Interest Income	0.18	0.07	0.06	0.01	0.03
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-4.54	-0.18	0.52	-1.78	0.00
Income
Income Before Tax	-13.20	-7.00	-10.80	-19.52	-10.89
Income Tax Expense	0.00	0.00	0.00	-0.09	0.00
Net Income	-13.20	-5.12	-12.73	-19.42	-10.89
Net Income - Continuous Operations	-13.20	-7.00	-10.80	-19.42	0.00
Net Income - Discontinued Operations	0.00	1.88	-1.94	0.00	0.00
EBITDA	-8.28	-6.89	-10.86	-17.69	-10.93
EBIT	-8.28	-6.89	-10.86	-17.74	-10.93
Depreciation & Amortization	0.00	0.00	0.00	0.06	0.00
Earnings Per Share
Basic EPS	-68.00	-4.00	-318.00	-26.00	-546.00
Diluted EPS	-68.00	-4.00	-318.00	-26.00	-546.00
Basic Shares Outstanding	0.19	1.42	0.04	0.74	0.02
Diluted Shares Outstanding	0.19	1.42	0.04	0.74	0.02